News

New approach to cat hair allergy: vaccine for cats is safe

In 2013, a team of researchers at the University Hospital Zurich developed an innovative method to combat cat hair allergies: Instead of humans, cats are to be vaccinated against the protein that triggers the allergy in humans. The research group led by Thomas Kündig, Prof. Dr. med., has now proven that the vaccine developed is safe for cats.

Cats are responsible for a large proportion of all pet allergies; around 10 percent of the population suffer from cat hair allergies. Animal hair allergies are caused by certain animal proteins. These are found, for example, on the dander, fur or in the saliva and tears of the animals. The proteins in the cat’s saliva are transferred to the fur through licking and trigger the allergic reaction in humans through skin contact or inhalation of airborne particles or cat hair.

The most common symptoms are irritation of the skin, eyes and nose. In advanced stages, those affected can even develop asthma. Until now, pet owners could only have their symptoms treated or had to undergo a costly desensitization process lasting several years or even give up their cat.

Hope for all cat allergy sufferers

Vaccination is well tolerated by the cat

In 2013, the research group led by allergologists and immunologists at the University Hospital Zurich developed a method that can be used to vaccinate cats against the body’s own protein “Fel d 1”, which triggers cat hair allergy in humans. As with an influenza vaccination, vaccination with the HypoCatTM cat vaccine causes the formation of antibodies. These neutralize the allergy-triggering protein Fel d 1 and reduce the reactive allergen. In this way, the symptoms in humans should be alleviated and, in the best case, prevented.

The researchers have now tested the vaccine in cats with regard to its tolerability, safety and immune response. To this end, the cats were given three basic vaccinations at three-week intervals. The researchers were able to show that the vaccine is tolerable and safe for cats. In addition, the vaccination produces antibodies that are detectable shortly after the vaccination and over a long period of time. These have neutralizing properties so that they bind the allergy-triggering protein Fel d 1 and prevent its ability to trigger the allergy. To prove this effect, the researchers analyzed tear samples from immunized cats. The analysis showed that the Fel d 1 protein in the tear fluid decreases after vaccination and is also less reactive. In this way, the allergic reaction in cat allergy sufferers could be reduced or even prevented. The research group is now investigating whether this is actually the case. Marketing authorization for the HypoCatTM vaccine is planned for 2022 in Europe and the USA.

To the study:

Responsible Department